Voyager Therapeutics(VYGR)
Focus: Voyager Therapeutics is a public-stage biotechnology company focused on AAV capsid gene therapy, headquartered in Lexington, MA, with a primary focus on neurodegenerative diseases including Alzheimer's, Parkinson's, and Huntington's disease.
Profile data last refreshed 7h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Voyager Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Voyager Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Voyager Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$250M
Pipeline & Clinical Trials
Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies
Parkinson's DiseaseClinical Trials (1)
NCT03733496Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies
N/AHelp build intelligence for Voyager Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.